Antimicrobial Stewardship in the Emergency Department Observation Unit: Definition of a New Indicator and Evaluation of Antimicrobial Use and Clinical Outcomes.

Emergency Department antimicrobial agents antimicrobial stewardship bloodstream infection health metrics

Journal

Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404

Informations de publication

Date de publication:
12 Apr 2024
Historique:
received: 22 02 2024
revised: 27 03 2024
accepted: 10 04 2024
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 26 4 2024
Statut: epublish

Résumé

We aimed to define a novel indicator for monitoring antimicrobial use specifically in the Emergency Department Observation Unit (EDOU) and to assess the long-term impact of an institutional education-based antimicrobial stewardship program (ASP) on the antimicrobial prescribing pattern and clinical outcomes in this setting. A quasi-experimental interrupted time-series study was performed from 2011 to 2022. An educational ASP was implemented at the EDOU in 2015. To estimate changes in antimicrobial use, we designed an indicator adjusted for patients at risk of antimicrobial prescribing: defined daily doses (DDDs) per 100 patients transferred from the Emergency Department to the Observation Unit (TOs) per quarter. The number of bloodstream infections (BSIs) and the crude all-cause 14-day mortality were assessed as clinical outcomes. Antimicrobial use showed a sustained reduction with a trend change of -1.17 DDD per 100 TO and a relative effect of -45.6% (CI95% -64.5 to -26.7), particularly relevant for meropenem and piperacillin-tazobactam, with relative effects of -80.4% (-115.0 to -45.7) and -67.9% (-93.9 to -41.9), respectively. The incidence density of all BSIs increased significantly during the ASP period, with a relative effect of 123.2% (41.3 to 284.7). The mortality rate remained low and stable throughout the study period, with an absolute effect of -0.7% (-16.0 to 14.7). The regular monitoring of antimicrobial use in the EDOU by using this new quantitative indicator was useful to demonstrate that an institutional education-based ASP successfully achieved a long-term reduction in overall antimicrobial use, with a low and steady BSI mortality rate.

Identifiants

pubmed: 38667032
pii: antibiotics13040356
doi: 10.3390/antibiotics13040356
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Regional Health Ministry of Andalucia, Spain
ID : PI-0361-2010

Auteurs

Ana Belén Guisado-Gil (AB)

Department of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Department of Pharmacy, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.

Marta Mejías-Trueba (M)

Department of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Department of Pharmacy, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.

Germán Peñalva (G)

Department of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.

Manuela Aguilar-Guisado (M)

Department of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.

Jose Molina (J)

Department of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.

Adelina Gimeno (A)

Department of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.

Rocío Álvarez-Marín (R)

Department of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.

Julia Praena (J)

Department of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.

Claudio Bueno (C)

Emergency Department, Virgen del Rocío University Hospital, 41013 Seville, Spain.

José Antonio Lepe (JA)

Department of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.

María Victoria Gil-Navarro (MV)

Department of Pharmacy, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.

José Miguel Cisneros (JM)

Department of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, 41013 Seville, Spain.
Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain.

Classifications MeSH